Jump to content

NY-ESO-1

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by BG19bot (talk | contribs) at 06:49, 11 February 2016 (WP:CHECKWIKI error fix. Broken bracket. Do general fixes if a problem exists. -). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

NY-ESO-1 is a human tumor antigen of the cancer/testis family.[1]

It is highly expressed in many poor-prognosis melanomas.[2]

It is being studied as possible target for a cancer vaccine or immunotherapy.

It is a target for some experimental engineered T-cell therapies for myeloma.[3]

See also

References

  1. ^ "NY-ESO-1: review of an immunogenic tumor antigen". Adv Cancer Res. 2006;95:1-30. 2006. {{cite journal}}: Unknown parameter |authors= ignored (help)
  2. ^ NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005
  3. ^ NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015 Aug;21(8):914-21. doi:10.1038/nm.3910.

Further reading


Stub icon

This protein-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=NY-ESO-1&oldid=704382413"